Related Experiment Video
Updated: Nov 9, 2025
23:33
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
84.1K
Janus Kinase Inhibitors and Risk of Venous Thromboembolism: A Systematic Review and Meta-analysis
Jawad Bilal1, Irbaz Bin Riaz2, Syed Arsalan Ahmed Naqvi3
1Division of Rheumatology, University of Arizona, Tucson.
Mayo Clinic Proceedings
|April 12, 2021
Summary
This study found no significant increase in venous thromboembolism (VTE) risk among patients treated with Janus kinase (JAK) inhibitors. Current data is insufficient to confirm a JAK inhibitor-associated VTE risk.
Area of Science:
- Pharmacology
- Clinical Trials
- Medical Research
Background:
- Janus kinase (JAK) inhibitors are used to treat various inflammatory and autoimmune conditions.
- Concerns have been raised regarding the potential risk of venous thromboembolism (VTE) associated with JAK inhibitor therapy.
Purpose of the Study:
- To systematically assess the risk of VTE in patients receiving Janus kinase (JAK) inhibitors.
- To synthesize evidence from randomized, placebo-controlled trials regarding VTE risk with JAK inhibitors.
Main Methods:
- A comprehensive literature search was conducted across multiple databases up to December 2019.
- Data from 29 randomized, placebo-controlled trials involving 13,910 patients were analyzed.
- Odds ratios and 95% confidence intervals were calculated using a random-effects model, with certainty assessed by the GRADE approach.
Main Results:
- No statistically significant association was found between JAK inhibitor use and an increased risk of VTE (OR, 0.91; 95% CI, 0.57 to 1.47).
- The analysis showed low certainty due to serious imprecision, with no interaction detected based on drug dose, indication, or follow-up length.
- Bayesian analysis yielded consistent results with the primary analysis.
Conclusions:
- Currently available data are insufficient to support an increased risk of VTE associated with JAK inhibitors.
- Further research with robust data is needed to definitively establish the VTE risk profile of JAK inhibitors.
Related Concept Videos
01:29Venous Thrombosis III: Interprofessional Care
94
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
94
01:30Venous Thrombosis I: Introduction
104
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
104
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.6K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.6K
01:20Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
100
The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
100
01:30Venous Thrombosis IV: Nursing Management
74
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
74
01:20The JAK-STAT Signaling Pathway
10.0K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
10.0K